β2 andrenergic polymorphism detection

• US 7,211,381 B1
• Filed: 04/04/2000
• Issued: 05/01/2007
• Est. Priority Date: 04/04/2000
• Status: Expired due to Fees

• Current Assignee: Abbott Laboratories
• Original Assignee: Abbott Laboratories
• Inventors: Yu, Hong, Merchant, Barbara T.
• Primary Examiner(s): Johannsen; Diana B.
• Application Number:
  US09/542,718
• Time in Patent Office: 2,583 Days
• Field of Search: 435/6, 435/15, 435/91.2, 435/194, 536/23.1, 536/23.5, 536/24.31, 536/24.33
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: Y10S 435/81 Packaged device or kit

Abstract

Nucleic acid sequences are provided that are useful as amplification primers and hybridization probes for amplifying and detecting target sequence from the β2 adrenergic receptor gene. The primers and probes can be employed in amplification based methods for detecting the presence of the target sequence in a test sample.

Claims

1. A combination of nucleic acids comprising a first nucleic acid consisting of the nucleotide sequence SEQ ID NO. 2 and optionally one or more labels, and a second nucleic acid consisting of the nucleotide sequence SEQ ID NO. 3 and optionally one or more labels.

3. A method of amplifying a β

2 adrenergic receptor target sequence comprising the steps of;

(a) forming a reaction mixture comprising nucleic acid amplification reagents, the combination of nucleic acids of claim 1, and a test sample suspected of containing the target sequence; and

(b) subjecting the mixture to amplification conditions to generate at least one copy of the target sequence.

4. A method for detecting a target sequence in a test sample comprising the steps of:

(a) forming a reaction mixture comprising nucleic acid amplification reagents, the combination of nucleic acids of claim 1, and a test sample suspected of containing the target sequence;

(b) subjecting the mixture to amplification conditions to generate an amplification product;

(c) hybridizing a probe consisting of a nucleotide sequence selected from the group consisting of SEQ ID NO. 4 and SEQ ID NO. 5, and optionally one or more labels, to the amplification product to form a hybrid; and

(d) detecting the hybrid as an indication of the presence of the target sequence in the test sample.

6. The combination of nucleic acids of claim 1, wherein one or more of the nucleic acids includes said one or more labels.

8. The method of claim 4, wherein the probe includes said one or more labels.

2. A combination of nucleic acids for detecting a target sequence comprising a first nucleic acid consisting of the nucleotide sequence SEQ ID NO. 2 and optionally one or more labels, a second nucleic acid consisting of the nucleotide sequence SEQ ID NO. 3 and optionally one or more labels, and a third nucleic acid consisting of a nucleotide sequence selected from the group consisting of SEQ ID NO. 4 and SEQ ID NO. 5, and optionally one or more labels.

7. The combination of nucleic acids of claim 2, wherein one or more of the nucleic acids includes said one or more labels.

5. A kit for amplifying a β

2 adrenergic receptor target sequence comprising;

(a) a first nucleic acid consisting of the nucleotide sequence SEQ ID NO. 2 and optionally one or more labels, and a second nucleic acid consisting of the nucleotide sequence SEQ ID NO. 3 and optionally one or more labels; and

(b) amplification reagents.

9. The kit of claim 5, wherein the first nucleic acid includes said one or more labels.

10. The kit of claim 5, wherein the second nucleic acid includes said one more labels.